Please provide your email address to receive an email when new articles are posted on . Five attendees at the American Diabetes Association Scientific Sessions were removed from the meeting after ...

Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. Five days after five ...

Amid intense backlash, the head of the American Diabetes Association posted a video Wednesday apologizing for the organization’s decision on Friday to forcefully remove five leading diabetes ...

The CEO of the American Diabetes Association (ADA) has apologized to five members who were escorted by police out of the organization's annual meeting in New Orleans last week after they distributed ...

New ADA 2026 data show diabetic ketoacidosis hospitalizations rising 24%, driven by poor ketone monitoring and symptom recognition gaps across all ages. A key driver of that burden is recognition—or ...

It’s not uncommon for employers to run into trouble with the ADA when it comes to accommodating workers with diabetes, for whom breaks are a common need. In December 2023, UPS paid $150,000 to settle ...

It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans featured more chatter on obesity drugs and pipeline programs than those ...

Boehringer Ingelheim spent the weekend pointing to survodutide's “targeted” weight loss, but the latest data couldn’t shake off concerns about the obesity drug’s tolerability. The deep dive into ...

NEW ORLEANS -- In the wake of clinicians and researchers being kicked out of the American Diabetes Association (ADA) meeting here, at least two of the organization's leaders have resigned.

As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its partner Roche helped get the show rolling with a deep dive into their ...

Five leading scientists were ousted from the annual meeting of the American Diabetes Association (ADA) in New Orleans on Friday. Their crime: handing out copies of an editorial, published in the ...

Late-breaking data for retatrutide, CagriSema, survodutide, and oral elecoglipron are poised to reshape near-term formulary strategy and utilization management for obesity and metabolic disease.